TODAY'S HEADLINES
The Centers for Disease Control and Prevention, with the help of the American Pharmacists Association Foundation, has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists. » More |
|
The new law regulating drug-compounding facilities, signed by President Obama at the end of November, did not provide all of the authority FDA sought, but agency officials believe "a great deal" of safety enhancements could be achieved with the new standards. » More |
|
FDA has issued a warning that clobazam (Onfi) can cause Stevens-Johnson syndrome and toxic epidermal necrolysis at any time during treatment. These serious skin reactions are rare, but can cause permanent harm and may lead to death. » More |
|
FDA is warning healthcare professionals of the rare but serious risk of heart attack and death with use of cardiac nuclear stress test agents regadenoson (Lexiscan) and adenosine (Adenoscan). » More |
Continuing Education
This month, Drug Topics offers the first of a two-part CPE series, "MTM considerations in multiple sclerosis." Earn up to 2 credits by completing this knowledge-based activity. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career. |
|
|
Like
Tweet
